Vaginal estrogen: how it works, safety and who it is for

Vaginal estrogen is a low dose of estrogen placed directly in the vagina as a cream, tablet, insert or ring. It treats the genitourinary syndrome of menopause (dryness, irritation, pain with sex and urinary symptoms) by restoring tissue that thins when estrogen falls. Because very little reaches the bloodstream, it does not relieve hot flashes, a progestogen is generally not needed, and long-term studies have not linked it to heart disease or cancer.

Vaginal versus systemic estrogen

	Low-dose vaginal estrogen	Systemic estrogen (pill, patch, gel, spray)
Treats	Vaginal dryness, pain with sex, urinary symptoms	Hot flashes and night sweats, bone loss, and vaginal symptoms
Blood estrogen	Minimal absorption	Raised throughout the body
Progestogen needed if you have a uterus	Generally no	Yes
Boxed warning after the 2025 FDA change	Removed on revised labels	Endometrial cancer warning kept for estrogen-alone products
First choice when only genitourinary symptoms bother you	Yes	No

The Menopause Society’s 2022 position statement says low-dose vaginal products are preferred over systemic therapy when estrogen is used only for genitourinary symptoms, and recommends them when over-the-counter moisturizers and lubricants have not given enough relief. Our guide to vaginal moisturizers and lubricants covers those first steps.

What it treats

The genitourinary syndrome of menopause, described in our GSM guide, includes genital dryness, burning and irritation; poor lubrication and pain with sex; and urinary urgency, painful urination and recurrent urinary tract infections. The Menopause Society finds vaginal estrogen effective for these symptoms, with no evidence that one preparation is safer or more effective than another. It may also help prevent recurrent UTIs and reduce overactive bladder and urge incontinence, whereas systemic hormone therapy can increase stress incontinence. More in our guide to recurrent UTIs after 40.

The trials behind one 3-month estradiol ring give a sense of the effect. In a 12-week US study comparing it with an estrogen cream, clinicians rated vaginal symptoms improved in 83 percent of ring users and 82 percent of cream users. Among ring users, painful urination improved in 74 percent and urinary urgency in 65 percent.

The forms

Low-dose options in the US include creams, vaginal tablets, a soft-gel vaginal insert and a ring replaced every 3 months. All contain estradiol except one cream, which contains conjugated estrogens. The Menopause Society advises placing creams, tablets and inserts in the lower third of the vagina, which improves symptom relief and reduces absorption. One other ring is designed to deliver systemic levels; it treats hot flashes and counts as systemic therapy.

ACOG lists the products shown to keep blood estradiol below 20 pg/mL: the 4-microgram insert, the 7.5-microgram ring, and the 10-microgram tablets and inserts.

How much reaches the bloodstream

The ring’s label offers the clearest numbers. It releases about 7.5 micrograms of estradiol a day for 90 days. For comparison, the ovaries of a woman with regular cycles release 70 to 500 micrograms a day. After a brief rise in the first hours, blood estradiol in a study of 222 women averaged 7.8, 7.0, 7.0 and 8.1 pg/mL at weeks 12, 24, 36 and 48, within the range seen in untreated women. About 8 percent of the daily dose was absorbed into the bloodstream unchanged.

Safety

The uterine lining. The Menopause Society says a progestogen is generally not indicated with low-dose vaginal estrogen, although trial data on endometrial safety beyond one year are lacking. In the ring’s US study, none of 58 women with a uterus showed endometrial overstimulation, compared with 4 of 35 (11 percent) using the estrogen cream it was tested against. Bleeding after menopause always needs evaluation.

Heart disease and cancer. In the Women’s Health Initiative Observational Study, 45,663 women aged 50 to 79 who did not use systemic estrogen were followed for a median of 7.2 years. Among women with a uterus, vaginal estrogen users had no higher risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer or blood clots than nonusers, and lower risks of coronary heart disease, fracture and death from any cause. Observational data cannot prove cause, but The Menopause Society notes the Nurses’ Health Study found the same reassuring pattern.

Side effects. In the ring’s two pivotal trials, headache was reported by 13 percent of ring users and 16 percent of cream users, vaginal discharge by 7 and 3 percent, and 5.4 percent stopped the ring because of a side effect, most often vaginal discomfort or digestive symptoms.

What the 2025 label change means

For more than twenty years, vaginal estrogen carried the same boxed warning as systemic hormone therapy. In November 2025 the FDA asked manufacturers of all menopausal hormone products, including vaginal ones, to remove cardiovascular disease, breast cancer and probable dementia from the boxed warning, to keep the endometrial cancer warning only on systemic estrogen-alone products, and to condense vaginal labels around the information most relevant to local use. The ring’s revised label, approved in February 2026, has no boxed warning. Labels are being updated product by product, so a package insert printed earlier may still show the old box. The wider change is explained in Is hormone therapy safe?.

Who it suits, and who needs a closer look

It suits most women whose main problem is genitourinary, and The Menopause Society says it may be considered at any age and for extended duration. Unlike hot flashes, which usually fade, GSM tends to worsen with prolonged estrogen deficiency.

The ring’s label still lists the same contraindications as systemic estrogen: unexplained genital bleeding, known or suspected estrogen-dependent cancer, a current or past blood clot, stroke or heart attack, liver disease, and inherited clotting disorders. It also states that the relevance of systemic estrogen risks to the ring is not known. If one of these applies to you, the decision is individual.

After breast cancer. ACOG’s 2021 clinical consensus, reaffirmed in 2024, recommends nonhormonal treatments first. If they fail, low-dose vaginal estrogen may be used, including by women taking tamoxifen, and for women on aromatase inhibitors after shared decision-making with the oncologist. ACOG found no evidence of harm in studies totaling more than 4,000 survivors. A Danish cohort of 8,461 women with estrogen receptor-positive early breast cancer found no overall increase in recurrence with vaginal estrogen (relative risk 1.08) and no increase in mortality, but a higher recurrence risk in the subgroup on aromatase inhibitors (1.39). See our guide to non-hormonal options for breast cancer survivors.

Questions to ask

• Which form suits me, and how often will I use it?
• How long before I should expect improvement, and when will we review?
• Do my medical history or medications change whether this is right for me?
• What bleeding or discharge should I report?

An OB-GYN can examine you, rule out other causes of your symptoms and help you choose a product.